The Inhibitory Effect of Cranberry Juice on Phenytoin Metabolism by Human Liver Microsomes

Kentarou USHIJIMA*1  Taka-aki KOSHIMIZU*2  Akio FUJIMURA*1

*1 Divisions of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan
*2 Divisions of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan

CYP2C9 is involved in the metabolism of many drugs such as warfarin and phenytoin (PHT). It is well known that some foods cause pharmacokinetic alterations of drugs and lead to toxicity. Regarding the interaction caused by cranberry juice (CrJ), its influence on the metabolism of warfarin, a CYP2C9 substrate, is controversial. In addition, information concerning the influence of CrJ on the pharmacokinetics of other substrate drugs of CYP2C9 is not available. To examine the inhibitory effect of CrJ on the metabolism of PHT, we performed experiments using a baculovirus expression microsome system and human liver microsome assay. CrJ concentration-dependently inhibited the substrate metabolism both in a baculovirus-expressed microsome system and in human liver microsome assay. These data support the idea that CrJ inhibits CYP2C9 activity, and the subsequent metabolism of drugs metabolized by CYP2C9. In this study, we did not identify the specific substance(s) which inhibits CYP2C9 activity. However, as CrJ did not enhance the PHT accumulation in 3D-HepG2 cells, it is thought that the penetration into hepatic cells of inhibitory substances in CrJ seems to be small.

Key words : cranberry juice, CYP2C9, human liver microsomes, interaction, phenytoin

Introduction

CYP2C9 is involved in the metabolism of many drugs including (S)-warfarin, tolbutamide, non-steroidal anti-inflammatory drugs and phenytoin (PHT)\(^1,2\). Some drugs with a narrow therapeutic range such as (S)-warfarin and PHT are particularly critical because even small pharmacokinetic and/or pharmacodynamic alterations can lead to toxicity or ineffectiveness. Regarding this issue, the interaction of foods and beverages with drugs should be taken into consideration in clinical practice. Recently, several case reports showed that patients on warfarin therapy suffered from a profound hypoprothrombinemia after the ingestion of cranberry juice (CrJ)\(^3,4\). These data led us to speculate that CrJ inhibits CYP2C9 activity. On the other hand, there are reports indicating that CrJ has a minimal effect on the pharmacokinetics and pharmacodynamics of warfarin\(^5,6\). However, we think that it is too early to reach a conclusion about the effect of CrJ on CYP2C9 activity, because, although CrJ is reported to inhibit metabolism of CYP2C9 substrates\(^7\), such effect of CrJ has not been sufficiently evaluated \textit{in vitro}, and thus there are controversial results between \textit{in vivo} and \textit{in vitro} findings.

To address the issue, we examined the effect of CrJ on the metabolism of PHT, another CYP2C9 substrate\(^8\). In this study, we determined the inhibitory effect of CrJ on CYP2C9 activity using an available commercialized inhibitor-screening kit. We also examined the influence of CrJ on the PHT metabolism by human liver microsomes.

Materials and Methods

1. Materials

The beverage used in this study was cranberry juice (containing 27% cranberry; Ocean Spray Cranberry, Inc., Lakeville-Middleboro, MA). Pooled human liver microsomes (from 15 donors) and CYP2C9 inhibitor screening kit were obtained from BD Bioscience (Franklin Lakes, NJ). Sodium Phenytion (5w/v%) was purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). Sulfaphenazole (SFZ), fluvoxamine maleate, rifampicin and Dulbecco’s Modified Eagle Medium (DMEM) were...
obtained from Sigma-Aldrich (St. Louis, MO).

2. Extraction of beverage with ethyl acetate
Preparation of the cranberry juice (CrJ) extract was performed according to the method reported previously. CrJ was mixed with 3-fold volumes of ethyl acetate and shaken vigorously for 20 min, and the mixture was centrifuged at 900 g for 10 min. The aqueous phase was discarded and the organic layer was evaporated to dryness under a stream of nitrogen. The residue was reconstituted with methanol (or acetonitrile in MFC-kit experiment according to the recommendation in the instruction manual) of one-fifth the initial respective volume of juice. The reconstituted solution was designated as a 5-fold concentrate (500% extract).

3. Effect of CrJ extracts on the metabolism of CYP2C9 substrate
The inhibitory effect of CrJ extract and SFZ on CYP2C9 activity was determined by baculovirus expression system using fluorescence substrate (MFC: 7-methoxy-4-trifluoro-methylcoumarin) (BD Bioscience). The experiment was performed according to the instruction manual: 100 μL of the reaction mixture contained NADP, glucose 6-phosphate, glucose-6-phosphate dehydrogenase and MgCl2 with appropriate concentrations of CrJ extract (final extract concentration; 0.0046–10%) or SFZ (final concentration; 0.005–10 μM) and was pre-incubated for 10 min at 37°C. The second reaction was started by the addition of 100 μL of the substrate mixture containing MFC (final concentration: 75 μM) and cDNA-expressed CYP2C9, P450 reductase and cytochrome b5 using a baculovirus expression system in insect cell microsomes, and incubated for 45 min at 37°C. The reaction was stopped by the addition of 120 μL of 50 mM NaOH and PHT concentration in the solution was automatically measured by fluorescence polarization immunoassay (FPIA) method (TDx®, Abbott Japan, Co., Ltd., Tokyo, Japan). The intra- and inter-assay coefficients of variation, determined by 5 and 20 μg/mL of PHT were better than 5%.

4. Influence of CrJ on the metabolism of PHT by human liver microsomes
Human liver microsome assay was performed according to the previous report with a minor modification. In brief, 280 μL of reaction mixture was pre-incubated for 10 min at 37°C by addition of human liver microsomes (final concentration: 0.48 mg/mL) to the NADPH-regenerating system (1.3 mM NADP, 3.3 mM glucose 6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 3.3 mM MgCl2) in 50 mM phosphate buffer (pH 7.4) with 10 μL of CrJ extract (final extract concentration; 0.3 and 1%) or SFZ solution (final concentration; 0.3 and 1.0 μM). After pre-incubation, 10 μL of PHT solution was added (final concentration: 10 μg/mL) and the mixture was incubated for 40 min at 37°C, because the rate of reduction of PHT remained constant for up to 40 min under these conditions.

The reaction was stopped by the addition of 1.2 mL of dichloromethane to the 300 μL of reaction mixture. Sample was shaken for 5 min vigorously and centrifuged at 750 g for 2 min. The aliquot layer was discarded and the organic solvent (900 μL) was evaporated to dryness under a stream of nitrogen. The residue was dissolved in 120 μL of 50 mM NaOH and PHT concentration in the solution was automatically measured by fluorescence polarization immunoassay (FPIA) method (TDx®, Abbott Japan, Co., Ltd., Tokyo, Japan). The intra- and inter-assay coefficients of variation, determined by 5 and 20 μg/mL of PHT were better than 5%.

5. Analysis of the inhibition pattern of CrJ on the PHT metabolism
To investigate the inhibition pattern of CrJ on PHT metabolism, Lineweaver-Burk plot analysis was performed. In brief, the reaction mixture contained human liver microsomes, the NADPH-regenerating system, CrJ extract (final extract concentration; 0.3% and 1%) was pre-incubated. After pre-incubation, PHT solution was added (final concentration: 4, 10 and 20 μg/mL) and the mixture was incubated for 40 min. After stopping the reaction, the applied procedures were the same as described above.

6. Influence of fluvoxamine on the metabolism of PHT by human liver microsomes
To investigate the suppression on the PHT metabolism caused by the CrJ-mediated inhibition of
CYP2C9, fluvoxamine was applied to this human liver microsome assay. As described above, the reaction mixture contained human liver microsomes, the NADPH-regenerating system, CrJ extract (final extract concentration: 1%), and fluvoxamine (final extract concentration: 1 and 10 μM) was pre-incubated. After pre-incubation, PHT solution was added (final concentration: 10 μg/mL) and the mixture was incubated for 40 min. After stopping the reaction, the applied procedures were the same as described above.

7. Influence of CrJ on the PHT accumulation in 3D-HepG2 cell

HepG2 cells in 3-dimension matrix (3D-HepG2) were purchased from Applied Cell Biotechnologies, Inc. (Kanagawa, Japan) and were cultured in DMEM with 10% fetal bovine serum (FBS) in a 24-well plate at 37°C with 5% CO₂. Cells were exposed to 20 μM rifampicin for 48hr to induce CYP enzymes. Thereafter, media were replaced with FBS-free DMEM containing 1 μM SFZ or 1% CrJ and cells were incubated for 1hr. After pre-treatment, PHT solution (final concentration: 10 μg/mL) was added to medium and cells were incubated for 40 min. Medium was collected and the reaction was stopped by washing with phosphate-buffered saline, followed by treating with 150 μL of 0.05N NaOH/0.1% Triton X-100 solution. The 3-dimension matrixes were incubated for 2hr at room temperature to digest cells for measurement of PHT and protein concentration. PHT concentration was measured by TDx®, and protein concentration was assayed by BCA protein assay reagent kit (Thermo Fisher Scientific Inc., Rockford, IL). PHT concentrations in 3D-HepG2 cells were calculated by the adjustment per mg protein.

8. Statistical analysis

Groups were compared by one-way ANOVA, followed by Tukey-Kramer’s test. p<0.05 was considered to be significant.

Results

1. Inhibitory effect of CrJ extract on the HFC production

To determine the inhibitory effect of CrJ extract on human CYP2C9 activity, we used a commercialized kit using a baculovirus expression system. SFZ, a positive control, concentration-dependently inhibited the HFC production, and the IC₅₀ value was calculated to be 0.15 μM (Fig.1a). As shown in Fig.1b, CrJ extract also showed concentration-dependent inhibition on the HFC production and the IC₅₀ value was 0.74%.

2. Influence of CrJ extracts on the metabolism of PHT by human liver microsomes

To examine whether the extract of CrJ inhibited the PHT metabolism, we performed an experiment using human liver microsome with NADPH-regeneration system. In this assay, we measured the parent drug (PHT), and calculated the reduction of PHT concentration, which was considered to represent metabolism of PHT. SFZ significantly inhibited
the PHT metabolism at 1 μM (Fig. 2a). CrJ also significantly inhibited the PHT metabolism with 0.3% and 1% of the sample (Fig. 2b).

3. Lineweaver-Burk plot for the inhibition of the PHT metabolism by CrJ

When same concentration of CrJ was added to microsome mixture with different PHT concentrations, the metabolizing ratio of PHT increased in a substrate-concentration-dependent manner. These two lines shown in Lineweaver-Burk plot crossed in the vicinity of Y-axis (the reciprocal of the metabolizing ratio) (Fig. 3).

4. Influence of fluvoxamine on the metabolism of PHT by human liver microsomes

To investigate whether CrJ inhibited the PHT metabolism directly by the suppression of CYP2C9 activity, fluvoxamine, the CYP1A2 and CYP2C19 inhibitor, was applied to this reaction. Fluvoxamine per se did not inhibit the PHT metabolism (Fig. 4). However, 1% of CrJ plus 10 μM fluvoxamine significantly decreased the PHT metabolism.

5. Influence of CrJ on the PHT accumulation in 3D-HepG2 cells

To investigate the penetration into hepatic cells of inhibitory substances in CrJ, HepG2 cells in 3-dimension matrix (3D-HepG2) were used. The decreases in PHT concentration in media did not significantly differ among these groups (data not shown). PHT concentration in 3D-HepG2 cells in the SFZ group was significantly higher than that in the control group (Fig. 5). On the other hand, PHT concentration in the CrJ group was slightly increased, but it did not reach a statistical significance.

Discussion

In this study, we examined the inhibitory effect of CrJ extract on the CYP2C9 activity. First experiment using a baculovirus expression system showed that CrJ extract inhibited the metabolite production concentration-dependently. A previous report showed that CrJ had moderate inhibitory potential on flurbiprofen hydroxylation by human liver microsomes5, which is similar to the present data. The IC₅₀ value of CrJ was approximately 3-fold higher in their
report than in this study. However this parameter can not be directly compared between the different studies because the IC₅₀ value depends on the substrate used and substrate concentration even if the same enzyme is inhibited.

In the second experiment, we examined an interaction between CrJ and PHT using human liver microsomes. SFZ, a positive control, significantly suppressed the PHT metabolism by 1.0 µM and the IC₅₀ value was estimated to be 0.3-1.0 µM. The IC₅₀ value for SFZ on the CYP2C9 inhibition was reported in the range of 0.1-1.0 µM[11,13], and therefore, we think that the present assay was valid. As to CrJ, its extract also concentration-dependently inhibited the PHT metabolism and the IC₅₀ value was estimated to be 0.3-1.0%, which is similar to that in the previous assay. In addition, to determine potential mechanism in the enzymatic-reaction inhibition of the PHT metabolism by CrJ, Lineweaver-Burk plot analysis was performed. The present finding indicates that the mode of the influence of CrJ on the PHT metabolism is a competitive inhibition. Thus, these findings support the hypothesis that CrJ inhibits the metabolism of CYP2C9 substrates.

Several biases were involved in the present experimental procedures. First, we used the organic concentrate extract of CrJ. Using the concentrate extract, we can test each solvent at the same volume in each reaction mixture. However, this approach can not evaluate the potential effect of aqueous components of beverages. Second, because we used TDx® system of PHT which can not measure the metabolites, we measured the parent drug alone.

When human liver microsome assay was performed without NADPH-regeneration systems, PHT concentration was not changed from base-line level (data not shown). Therefore, it is unlikely that the inhibition of PHT metabolism by CrJ was via non-enzymatic reaction. PHT is reported to be mainly oxidized by CYP2C9 and partially by CYP2C19[8]. To investigate whether CrJ especially inhibited CYP2C9 activity in PHT metabolism, we applied fluvoxamine, the CYP1A2 and CYP2C19 inhibitor[4,15], in this microsome assay. Although fluvoxamine did not suppress the PHT metabolism, CrJ with fluvoxamine significantly decreased the PHT metabolism by about 30%. Thus, we think that CrJ inhibited the PHT metabolism mainly through the suppression of CYP2C9 activity.

We did not determine the substance(s) which inhibited the PHT metabolism in this assay. Thus, it remains to be determined whether the substance(s) which decreases the PHT metabolism in the present assay has an efficient bioavailability to inhibit the CYP2C9 activity in vivo. To address this issue, we performed an experiment using 3D-HepG2 cells to examine the penetration of the inhibitory substance(s) into hepatic cells. SFZ significantly elevated the PHT concentration in cells without accelerating the PHT uptake, which might be due to the inhibition of CYP2C9 activity by SFZ. However, CrJ did not significantly increase the PHT concentration. Based on these findings, we think that the penetration of inhibitory substance(s) contained in CrJ into hepatic...
cells is small, and the inhibitory effect of CrJ is negligible in vivo, if any.

In summary, the present in vitro studies showed that CrJ extract inhibited the PHT metabolism by human liver microsomes. These data are comparable with the idea that CrJ inhibits the metabolism of drugs metabolized by CYP2C9. We did not perform a clinical trial in patients or healthy volunteers, because of the safety concern about PHT with a narrow therapeutic range\(^\text{16}\). However, the present study suggests that the inhibitory effect of CrJ on the metabolism of CYP2C9 substrates is small in human subjects. Since in vivo study of a food-drug interaction is complicated by a number of factors, it seems difficult to extrapolate the in vitro data into in vivo. To determine whether the ingestion of CrJ causes the pharmacokinetic and pharmacodynamic alterations in human subjects, further clinical studies using CYP2C9 substrates other than warfarin or phenytoin are needed.

Acknowledgement
We thank Kanoko Egashira (Nagasaki University Hospital) and Yosuke Taniguchi (Kyushu University) for their valuable advice in the microsomal experiments. We also thank Tomohiro Maekawa (Jichi Medical University) for his experimental assistance.

References
8) Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-3.
14) Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283: 434-42.